Evidence map›Paper›PMID 42745664›Full record

ArticleNucleic acids research2026

Androgen receptor drives divergent chromatin accessibility programs in benign and malignant prostate epithelial cells.

Konsta Kukkonen, Ebrahim Afyounian, Hanna Rauhala, Matti Nykter, Alfonso Urbanucci, Leena Latonen, Tapio Visakorpi

Abstract read
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Konsta KukkonenFaculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere University Hospital, 33520 Tampere, Finland.ORCID 0000-0001-5819-933X
Ebrahim AfyounianFaculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere University Hospital, 33520 Tampere, Finland.ORCID 0000-0002-0755-0131
Hanna RauhalaFaculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere University Hospital, 33520 Tampere, Finland.ORCID 0000-0001-7796-9117
Matti NykterFaculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere University Hospital, 33520 Tampere, Finland.ORCID 0000-0001-6956-2843
Alfonso UrbanucciFaculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere University Hospital, 33520 Tampere, Finland.ORCID 0000-0003-2931-3652
Leena LatonenInstitute of Biomedicine, University of Eastern Finland, 70211 Kuopio, Finland.ORCID 0000-0003-4502-2193
Tapio VisakorpiFaculty of Medicine and Health Technology, Tampere University and Tays Cancer Centre, Tampere University Hospital, 33520 Tampere, Finland.ORCID 0000-0002-5004-0364

Funding

Cancer Foundation FinlandCompetitive State Research Financing of the Expert Responsibility area of Tampere University HospitalFinnish Cultural FoundationNorwegian Cancer Society 198016Norwegian Cancer Society 273672Research Council of Finland 279270Research Council of Finland 349314Research Council of Finland 352828Research Council of Finland 357490Sigrid Jusélius FoundationTampere Institute for Advanced Study and Cancer Society of FinlandTampere University
6 · The paper itself

Abstract

Androgen receptor (AR) activation alters chromatin structure in prostate cancer (PC) cells, but its impact in nonmalignant prostate epithelial cells (NPEC) remains poorly characterized due to lack of representative models. We leveraged our previously established NPEC (RWPE-1-AR and RWPE-1-Ctrl) and PC (LNCaP-pcDNA3.1 and LNCaP-ARhi) cell models to profile androgen-driven chromatin responses using assay for transposase-accessible chromatin with sequencing (ATAC-seq). In the absence of androgen, NPEC and PC cells exhibited widespread differences in chromatin accessibility. Androgen stimulation amplified these differences, revealing distinct AR-mediated chromatin remodeling between the cell types. Androgen-sensitive regions were enriched for nuclear receptor binding sites (AR and glucocorticoid receptor), with AP-1 motifs more prominent in NPEC and FOXA1 motifs in PC cells. Comparison with ATAC-seq profiles obtained from clinical samples showed that NPECs resembled benign prostate hyperplasia, while PC cells mirrored untreated and castration-resistant PC, supporting the relevance of our models. Integration of ATAC-seq and mRNA-sequencing (mRNA-seq) identified model-specific AR target genes, including CDKN1C/p57 in NPEC, which may contribute to the previously observed androgen-induced growth arrest in these cells. These findings demonstrate that AR activation reprograms chromatin accessibility in normal prostate epithelium, revealing fundamental regulatory differences compared to the tumor context and underscore the importance of physiologically relevant cell models.

Indexed as

ChromatinChromatin Assembly and DisassemblyEpithelial CellsProstateProstatic NeoplasmsReceptors, AndrogenAndrogensBinding SitesCell Line, TumorGene Expression Regulation, NeoplasticHepatocyte Nuclear Factor 3-alphaHumansMaleProstatic HyperplasiaReceptors, GlucocorticoidTranscription Factor AP-1AndrogensAR protein, humanChromatinFOXA1 protein, humanHepatocyte Nuclear Factor 3-alphaReceptors, AndrogenReceptors, GlucocorticoidTranscription Factor AP-1

Identifiers

PMID42745664
PMCPMC13578506

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.